Nanjing Heron Pharmaceutical Co.,Ltd.

Primary Study Objectives: 1. To evaluate the pharmacokinetic characteristics of HR1405-01 injection in participants with mild to moderate hepatic impairment and normal liver function. Secondary Study Objectives: 1. To evaluate the safety of HR1405-01 injection in participants with mild to moderate hepatic impairment and normal liver function. 2. To evaluate the pharmacokinetic characteristics of the metabolite M8 of HR1405-01 injection in participants with mild to moderate hepatic impairment and normal liver function.

Primary Study Objectives: 1. To evaluate the pharmacokinetic characteristics of HR1405-01 injection in participants with mild, moderate, and severe renal impairment and those with normal renal function. Secondary Study Objectives: 1. To evaluate the safety of HR1405-01 injection in participants with mild, moderate, and severe renal impairment and those with normal renal function; 2. To evaluate the pharmacokinetic characteristics of the metabolite M8 of HR1405-01 injection in participants with mild, moderate, and severe renal impairment and those with normal renal function.

Primary Study Objective: Using Ivocasert tablets (2 mg) manufactured by Nanjing Hairong Pharmaceutical Co., Ltd. as the test formulation and Ivocasert tablets (2 mg) manufactured by Kyowa Kirin Co., Ltd. as the reference formulation, we investigated the pharmacokinetic parameters and relative bioavailability of the two formulations after single administration in the fasting and fed states, and evaluated their bioequivalence. Secondary Study Objective: Evaluate the safety of the test and reference formulations in healthy study participants.